Home › Research › How common it is
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, Song L, Hanlon D et al.. Scientific reports, 2016-05-31
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Implementation of amyloid biomarkers in clinical practice would be accelerated if such biomarkers could be measured in blood. We analyzed plasma levels of Aβ42 and Aβ40 in a cohort of 719 individuals (the Swedish BioFINDER study), including patients with subjective cognitive decline (SCD), mild cognitive impairment (MCI), Alzheimer's disease (AD) dementia and cognitively healthy elderly, using a ultrasensitive immunoassay (Simoa platform). There were weak positive correlations between plasma and cerebrospinal fluid (CSF) levels for both Aβ42 and Aβ40, and negative correlations between plasma Aβ42 and neocortical amyloid deposition (measured with PET). Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups. However, during the preclinical or prodromal AD stages (i.e. in amyloid positive controls, SCD and MCI) plasma concentration of Aβ42 was just moderately decreased whereas Aβ40 levels were unchanged. Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease. In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain. Further, increased levels of Aβ in plasma are associated with vascular disease.
What this study adds
Evidence grade: Moderate
The record lists 719 participants. Higher blood (but not spinal-fluid) amyloid was associated with white matter lesions, microbleeds, hypertension, diabetes and heart disease. This is an early look at blood amyloid as a possible test: it reports associations in one research cohort, gives no diagnostic accuracy figures, and tested no treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., et al. (2016). Plasma β-amyloid in Alzheimer's disease and vascular disease. Scientific reports. https://doi.org/10.1038/srep26801
Vancouver
Janelidze S, Stomrud E, Palmqvist S, Zetterberg H, van Westen D, Jeromin A, et al. Plasma β-amyloid in Alzheimer's disease and vascular disease. Scientific reports. 2016. doi:10.1038/srep26801. PMID: 27241045.
BibTeX
@article{janelidze2016-27241045,
author = {Janelidze, S. and Stomrud, E. and Palmqvist, S. and Zetterberg, H. and van Westen, D. and Jeromin, A. and Song, L. and Hanlon, D. and others},
title = {{Plasma β-amyloid in Alzheimer's disease and vascular disease}},
journal = {Scientific reports},
year = {2016},
doi = {10.1038/srep26801},
pmid = {27241045},
url = {https://doi.org/10.1038/srep26801}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Plasma levels of Aβ42 and Aβ40 were reduced in AD dementia compared with all other diagnostic groups.
- Higher plasma (but not CSF) levels of Aβ were associated with white matter lesions, cerebral microbleeds, hypertension, diabetes and ischemic heart disease.
- In summary, plasma Aβ is overtly decreased during the dementia stage of AD indicating that prominent changes in Aβ metabolism occur later in the periphery compared to the brain.
- Further, increased levels of Aβ in plasma are associated with vascular disease.
Why it matters
In 719 people from the Swedish BioFINDER cohort, ranging from cognitively healthy to Alzheimer's dementia, blood levels of amyloid (Aβ42 and Aβ40) agreed only weakly with spinal-fluid levels and were clearly lower only at the dementia stage; in earlier stages Aβ42 was "just moderately decreased" and Aβ40 "unchanged". Higher blood (but not spinal-fluid) amyloid was associated with white matter lesions, microbleeds, hypertension, diabetes and heart disease. This is an early look at blood amyloid as a possible test: it reports associations in one research cohort, gives no diagnostic accuracy figures, and tested no treatment.
New to this subject? Start with our plain-English guide: Alzheimer's in numbers →
Study details
- Participants719
- Evidence strengthModerate
How this study scored 64/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Scientific reports) |
| Journal's citation record | 3 / 4 | Scientific Reports: journal h-index 463 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 719 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 6 / 7 | Cited 626 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 52.2 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 5 / 6 | Cited 34.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 47 other studies in this library |
| Still being cited | 3 / 4 | Cited 186 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 27241045) |
| Free to read | 2 / 2 | Free to read |
| Total | 64 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 21.
Later studies that cite this one
47 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in How common it is from nearby years
Also in How common it is
80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.